AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer.
Why Is Micro-Cap AIM ImmunoTech Stock Surging? AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.
5 Dividend Stocks to Hold for the Next 20 Years Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them!
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.
AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer AstraZeneca's Tagrisso with chemo significantly improves survival and progression-free outcomes in EGFR-mutant NSCLC, final trial data shows.
JPMorgan Goes Global With HOLA ETF—Stocks Plus Built‑In Crash Protection JPMorgan AM launched HOLA, an ETF that aims to generate income from foreign equities while mitigating risk through a laddered options overlay.
AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition AstraZeneca's anselamimab missed the main goal in a Phase 3 AL amyloidosis trial but showed promising benefit in a defined patient subgroup.
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the catalysts that could be driving the attention.
Why Is AbbVie Stock Trading Higher On Thursday? AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss.
Artelo Biosciences Analyst See It As An Emerging Biotech Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its candidate for depression.
NIKE, Datadog And Snap Are Among Top 11 Large Cap Gainers Last Week (June 30-July 4): Are The Others In Your Portfolio? 11 best performing large-cap stocks last week, including Symbotic, Nike, First Solar, Datadog, HPE, Summit Therapeutics, Carnival, POSCO, Wynn Resorts, SharkNinja, and Snap
